

Global Short-acting Recombinant Human Erythropoietin Drugs Market Growth 2023-2029

<https://marketpublishers.com/r/G0BDBFE79D8AEN.html>

Date: November 2023

Pages: 113

Price: US\$ 3,660.00 (Single User License)

ID: G0BDBFE79D8AEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

According to our LPI (LP Information) latest study, the global Short-acting Recombinant Human Erythropoietin Drugs market size was valued at US\$ 8968.6 million in 2022. With growing demand in downstream market, the Short-acting Recombinant Human Erythropoietin Drugs is forecast to a readjusted size of US\$ 14070 million by 2029 with a CAGR of 6.6% during review period.

The research report highlights the growth potential of the global Short-acting Recombinant Human Erythropoietin Drugs market. Short-acting Recombinant Human Erythropoietin Drugs are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Short-acting Recombinant Human Erythropoietin Drugs. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Short-acting Recombinant Human Erythropoietin Drugs market.

Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.

The market for short-acting recombinant human erythropoietin drugs is currently in a steady growth phase, with its size gradually expanding, and sales continuing to rise. These drugs find extensive use in the treatment of anemia, especially in patients with

chronic kidney disease, cancer chemotherapy recipients, and individuals requiring correction of hemoglobin levels pre-surgery. Future developments may include further expansion into additional clinical applications and more convenient administration routes, along with improved manufacturing techniques to meet the growing healthcare demands.

Key Features:

The report on Short-acting Recombinant Human Erythropoietin Drugs market reflects various aspects and provide valuable insights into the industry.

Market Size and Growth: The research report provide an overview of the current size and growth of the Short-acting Recombinant Human Erythropoietin Drugs market. It may include historical data, market segmentation by Type (e.g., Epoetin-alfa, Epoetin-beta), and regional breakdowns.

Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Short-acting Recombinant Human Erythropoietin Drugs market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.

Competitive Landscape: The research report provides analysis of the competitive landscape within the Short-acting Recombinant Human Erythropoietin Drugs market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.

Technological Developments: The research report can delve into the latest technological developments in the Short-acting Recombinant Human Erythropoietin Drugs industry. This include advancements in Short-acting Recombinant Human Erythropoietin Drugs technology, Short-acting Recombinant Human Erythropoietin Drugs new entrants, Short-acting Recombinant Human Erythropoietin Drugs new investment, and other innovations that are shaping the future of Short-acting Recombinant Human Erythropoietin Drugs.

Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Short-acting Recombinant Human Erythropoietin Drugs market. It includes factors influencing customer ' purchasing decisions, preferences for Short-acting Recombinant Human Erythropoietin Drugs

product.

Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Short-acting Recombinant Human Erythropoietin Drugs market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Short-acting Recombinant Human Erythropoietin Drugs market. The report also evaluates the effectiveness of these policies in driving market growth.

Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Short-acting Recombinant Human Erythropoietin Drugs market.

Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Short-acting Recombinant Human Erythropoietin Drugs industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.

Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Short-acting Recombinant Human Erythropoietin Drugs market.

Market Segmentation:

Short-acting Recombinant Human Erythropoietin Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Segmentation by type

Epoetin-alfa

Epoetin-beta

Darbepoetin-alfa

Others

Segmentation by application

Anemia

Kidney Disorders

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Amgen

Johnson & Johnson

Roche

Kyowa Kirin

LG Chem

Daewoong Pharmaceutical

Wockhardt

CJ Healthcare

3SBio

Kexing Biopharm

Harbin Pharmaceutical Group

Beijing Four Rings Bio-Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Short-acting Recombinant Human Erythropoietin Drugs market?

What factors are driving Short-acting Recombinant Human Erythropoietin Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Short-acting Recombinant Human Erythropoietin Drugs market opportunities vary by end market size?

How does Short-acting Recombinant Human Erythropoietin Drugs break out type, application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

2.1.1 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Sales 2018-2029

2.1.2 World Current & Future Analysis for Short-acting Recombinant Human Erythropoietin Drugs by Geographic Region, 2018, 2022 & 2029

2.1.3 World Current & Future Analysis for Short-acting Recombinant Human Erythropoietin Drugs by Country/Region, 2018, 2022 & 2029

2.2 Short-acting Recombinant Human Erythropoietin Drugs Segment by Type

2.2.1 Epoetin-alfa

2.2.2 Epoetin-beta

2.2.3 Darbepoetin-alfa

2.2.4 Others

2.3 Short-acting Recombinant Human Erythropoietin Drugs Sales by Type

2.3.1 Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2018-2023)

2.3.2 Global Short-acting Recombinant Human Erythropoietin Drugs Revenue and Market Share by Type (2018-2023)

2.3.3 Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Type (2018-2023)

2.4 Short-acting Recombinant Human Erythropoietin Drugs Segment by Application

2.4.1 Anemia

2.4.2 Kidney Disorders

2.4.3 Others

2.5 Short-acting Recombinant Human Erythropoietin Drugs Sales by Application

2.5.1 Global Short-acting Recombinant Human Erythropoietin Drugs Sale Market Share by Application (2018-2023)

2.5.2 Global Short-acting Recombinant Human Erythropoietin Drugs Revenue and Market Share by Application (2018-2023)

2.5.3 Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Application (2018-2023)

3 GLOBAL SHORT-ACTING RECOMBINANT HUMAN ERYTHROPOIETIN DRUGS BY COMPANY

3.1 Global Short-acting Recombinant Human Erythropoietin Drugs Breakdown Data by Company

3.1.1 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Sales by Company (2018-2023)

3.1.2 Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Company (2018-2023)

3.2 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Revenue by Company (2018-2023)

3.2.1 Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Company (2018-2023)

3.2.2 Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Company (2018-2023)

3.3 Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Company

3.4 Key Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Product Location Distribution

3.4.2 Players Short-acting Recombinant Human Erythropoietin Drugs Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR SHORT-ACTING RECOMBINANT HUMAN ERYTHROPOIETIN DRUGS BY GEOGRAPHIC REGION

4.1 World Historic Short-acting Recombinant Human Erythropoietin Drugs Market Size

by Geographic Region (2018-2023)

4.1.1 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Sales by Geographic Region (2018-2023)

4.1.2 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Revenue by Geographic Region (2018-2023)

4.2 World Historic Short-acting Recombinant Human Erythropoietin Drugs Market Size by Country/Region (2018-2023)

4.2.1 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Sales by Country/Region (2018-2023)

4.2.2 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Revenue by Country/Region (2018-2023)

4.3 Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Growth

4.4 APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Growth

4.5 Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Growth

4.6 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Growth

5 AMERICAS

5.1 Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Country

5.1.1 Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2018-2023)

5.1.2 Americas Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2018-2023)

5.2 Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Type

5.3 Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Region

6.1.1 APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Region (2018-2023)

6.1.2 APAC Short-acting Recombinant Human Erythropoietin Drugs Revenue by Region (2018-2023)

- 6.2 APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Type
- 6.3 APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe Short-acting Recombinant Human Erythropoietin Drugs by Country
 - 7.1.1 Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2018-2023)
 - 7.1.2 Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2018-2023)
- 7.2 Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Type
- 7.3 Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs by Country
 - 8.1.1 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2018-2023)
 - 8.1.2 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2018-2023)
- 8.2 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Type
- 8.3 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Application
- 8.4 Egypt
- 8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Short-acting Recombinant Human Erythropoietin Drugs

10.3 Manufacturing Process Analysis of Short-acting Recombinant Human Erythropoietin Drugs

10.4 Industry Chain Structure of Short-acting Recombinant Human Erythropoietin Drugs

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Short-acting Recombinant Human Erythropoietin Drugs Distributors

11.3 Short-acting Recombinant Human Erythropoietin Drugs Customer

12 WORLD FORECAST REVIEW FOR SHORT-ACTING RECOMBINANT HUMAN ERYTHROPOIETIN DRUGS BY GEOGRAPHIC REGION

12.1 Global Short-acting Recombinant Human Erythropoietin Drugs Market Size Forecast by Region

12.1.1 Global Short-acting Recombinant Human Erythropoietin Drugs Forecast by Region (2024-2029)

12.1.2 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Revenue Forecast by Region (2024-2029)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Short-acting Recombinant Human Erythropoietin Drugs Forecast by Type

12.7 Global Short-acting Recombinant Human Erythropoietin Drugs Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Amgen

13.1.1 Amgen Company Information

13.1.2 Amgen Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications

13.1.3 Amgen Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)

13.1.4 Amgen Main Business Overview

13.1.5 Amgen Latest Developments

13.2 Johnson & Johnson

13.2.1 Johnson & Johnson Company Information

13.2.2 Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications

13.2.3 Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)

13.2.4 Johnson & Johnson Main Business Overview

13.2.5 Johnson & Johnson Latest Developments

13.3 Roche

13.3.1 Roche Company Information

13.3.2 Roche Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications

13.3.3 Roche Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)

13.3.4 Roche Main Business Overview

13.3.5 Roche Latest Developments

13.4 Kyowa Kirin

13.4.1 Kyowa Kirin Company Information

13.4.2 Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications

13.4.3 Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)

13.4.4 Kyowa Kirin Main Business Overview

13.4.5 Kyowa Kirin Latest Developments

13.5 LG Chem

13.5.1 LG Chem Company Information

13.5.2 LG Chem Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications

13.5.3 LG Chem Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)

13.5.4 LG Chem Main Business Overview

13.5.5 LG Chem Latest Developments

13.6 Daewoong Pharmaceutical

13.6.1 Daewoong Pharmaceutical Company Information

13.6.2 Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications

13.6.3 Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)

13.6.4 Daewoong Pharmaceutical Main Business Overview

13.6.5 Daewoong Pharmaceutical Latest Developments

13.7 Wockhardt

13.7.1 Wockhardt Company Information

13.7.2 Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications

13.7.3 Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)

13.7.4 Wockhardt Main Business Overview

13.7.5 Wockhardt Latest Developments

13.8 CJ Healthcare

13.8.1 CJ Healthcare Company Information

13.8.2 CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications

13.8.3 CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)

13.8.4 CJ Healthcare Main Business Overview

13.8.5 CJ Healthcare Latest Developments

13.9 3SBio

13.9.1 3SBio Company Information

13.9.2 3SBio Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications

13.9.3 3SBio Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)

13.9.4 3SBio Main Business Overview

- 13.9.5 3SBio Latest Developments
- 13.10 Kexing Biopharm
 - 13.10.1 Kexing Biopharm Company Information
 - 13.10.2 Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
 - 13.10.3 Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.10.4 Kexing Biopharm Main Business Overview
 - 13.10.5 Kexing Biopharm Latest Developments
- 13.11 Harbin Pharmaceutical Group
 - 13.11.1 Harbin Pharmaceutical Group Company Information
 - 13.11.2 Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
 - 13.11.3 Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.11.4 Harbin Pharmaceutical Group Main Business Overview
 - 13.11.5 Harbin Pharmaceutical Group Latest Developments
- 13.12 Beijing Four Rings Bio-Pharmaceutical
 - 13.12.1 Beijing Four Rings Bio-Pharmaceutical Company Information
 - 13.12.2 Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
 - 13.12.3 Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.12.4 Beijing Four Rings Bio-Pharmaceutical Main Business Overview
 - 13.12.5 Beijing Four Rings Bio-Pharmaceutical Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Short-acting Recombinant Human Erythropoietin Drugs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Table 2. Short-acting Recombinant Human Erythropoietin Drugs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)

Table 3. Major Players of Epoetin-alfa

Table 4. Major Players of Epoetin-beta

Table 5. Major Players of Darbepoetin-alfa

Table 6. Major Players of Others

Table 7. Global Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2018-2023) & (K Units)

Table 8. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2018-2023)

Table 9. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Type (2018-2023) & (\$ million)

Table 10. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Type (2018-2023)

Table 11. Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Type (2018-2023) & (US\$/Unit)

Table 12. Global Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2018-2023) & (K Units)

Table 13. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2018-2023)

Table 14. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Application (2018-2023)

Table 15. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Application (2018-2023)

Table 16. Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Application (2018-2023) & (US\$/Unit)

Table 17. Global Short-acting Recombinant Human Erythropoietin Drugs Sales by Company (2018-2023) & (K Units)

Table 18. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Company (2018-2023)

Table 19. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Company (2018-2023) (\$ Millions)

Table 20. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue

Market Share by Company (2018-2023)

Table 21. Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Company (2018-2023) & (US\$/Unit)

Table 22. Key Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Producing Area Distribution and Sales Area

Table 23. Players Short-acting Recombinant Human Erythropoietin Drugs Products Offered

Table 24. Short-acting Recombinant Human Erythropoietin Drugs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

Table 25. New Products and Potential Entrants

Table 26. Mergers & Acquisitions, Expansion

Table 27. Global Short-acting Recombinant Human Erythropoietin Drugs Sales by Geographic Region (2018-2023) & (K Units)

Table 28. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share Geographic Region (2018-2023)

Table 29. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Geographic Region (2018-2023) & (\$ millions)

Table 30. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Geographic Region (2018-2023)

Table 31. Global Short-acting Recombinant Human Erythropoietin Drugs Sales by Country/Region (2018-2023) & (K Units)

Table 32. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country/Region (2018-2023)

Table 33. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country/Region (2018-2023) & (\$ millions)

Table 34. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country/Region (2018-2023)

Table 35. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2018-2023) & (K Units)

Table 36. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country (2018-2023)

Table 37. Americas Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2018-2023) & (\$ Millions)

Table 38. Americas Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country (2018-2023)

Table 39. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2018-2023) & (K Units)

Table 40. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2018-2023) & (K Units)

Table 41. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Region (2018-2023) & (K Units)

Table 42. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Region (2018-2023)

Table 43. APAC Short-acting Recombinant Human Erythropoietin Drugs Revenue by Region (2018-2023) & (\$ Millions)

Table 44. APAC Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Region (2018-2023)

Table 45. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2018-2023) & (K Units)

Table 46. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2018-2023) & (K Units)

Table 47. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2018-2023) & (K Units)

Table 48. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country (2018-2023)

Table 49. Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2018-2023) & (\$ Millions)

Table 50. Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country (2018-2023)

Table 51. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2018-2023) & (K Units)

Table 52. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2018-2023) & (K Units)

Table 53. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2018-2023) & (K Units)

Table 54. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country (2018-2023)

Table 55. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2018-2023) & (\$ Millions)

Table 56. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country (2018-2023)

Table 57. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2018-2023) & (K Units)

Table 58. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2018-2023) & (K Units)

Table 59. Key Market Drivers & Growth Opportunities of Short-acting Recombinant Human Erythropoietin Drugs

Table 60. Key Market Challenges & Risks of Short-acting Recombinant Human

Erythropoietin Drugs

Table 61. Key Industry Trends of Short-acting Recombinant Human Erythropoietin Drugs

Table 62. Short-acting Recombinant Human Erythropoietin Drugs Raw Material

Table 63. Key Suppliers of Raw Materials

Table 64. Short-acting Recombinant Human Erythropoietin Drugs Distributors List

Table 65. Short-acting Recombinant Human Erythropoietin Drugs Customer List

Table 66. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Region (2024-2029) & (K Units)

Table 67. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 68. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Country (2024-2029) & (K Units)

Table 69. Americas Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 70. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Region (2024-2029) & (K Units)

Table 71. APAC Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 72. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Country (2024-2029) & (K Units)

Table 73. Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 74. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Country (2024-2029) & (K Units)

Table 75. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 76. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Type (2024-2029) & (K Units)

Table 77. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Type (2024-2029) & (\$ Millions)

Table 78. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Application (2024-2029) & (K Units)

Table 79. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Application (2024-2029) & (\$ Millions)

Table 80. Amgen Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors

Table 81. Amgen Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications

Table 82. Amgen Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 83. Amgen Main Business

Table 84. Amgen Latest Developments

Table 85. Johnson & Johnson Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors

Table 86. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications

Table 87. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 88. Johnson & Johnson Main Business

Table 89. Johnson & Johnson Latest Developments

Table 90. Roche Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors

Table 91. Roche Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications

Table 92. Roche Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 93. Roche Main Business

Table 94. Roche Latest Developments

Table 95. Kyowa Kirin Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors

Table 96. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications

Table 97. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 98. Kyowa Kirin Main Business

Table 99. Kyowa Kirin Latest Developments

Table 100. LG Chem Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors

Table 101. LG Chem Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications

Table 102. LG Chem Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 103. LG Chem Main Business

Table 104. LG Chem Latest Developments

Table 105. Daewoong Pharmaceutical Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors

Table 106. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin

Drugs Product Portfolios and Specifications

Table 107. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 108. Daewoong Pharmaceutical Main Business

Table 109. Daewoong Pharmaceutical Latest Developments

Table 110. Wockhardt Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors

Table 111. Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications

Table 112. Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 113. Wockhardt Main Business

Table 114. Wockhardt Latest Developments

Table 115. CJ Healthcare Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors

Table 116. CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications

Table 117. CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 118. CJ Healthcare Main Business

Table 119. CJ Healthcare Latest Developments

Table 120. 3SBio Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors

Table 121. 3SBio Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications

Table 122. 3SBio Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 123. 3SBio Main Business

Table 124. 3SBio Latest Developments

Table 125. Kexing Biopharm Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors

Table 126. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications

Table 127. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 128. Kexing Biopharm Main Business

Table 129. Kexing Biopharm Latest Developments

Table 130. Harbin Pharmaceutical Group Basic Information, Short-acting Recombinant

Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors

Table 131. Harbin Pharmaceutical Group Short-acting Recombinant Human

Erythropoietin Drugs Product Portfolios and Specifications

Table 132. Harbin Pharmaceutical Group Short-acting Recombinant Human

Erythropoietin Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 133. Harbin Pharmaceutical Group Main Business

Table 134. Harbin Pharmaceutical Group Latest Developments

Table 135. Beijing Four Rings Bio-Pharmaceutical Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors

Table 136. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications

Table 137. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 138. Beijing Four Rings Bio-Pharmaceutical Main Business

Table 139. Beijing Four Rings Bio-Pharmaceutical Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Short-acting Recombinant Human Erythropoietin Drugs
- Figure 2. Short-acting Recombinant Human Erythropoietin Drugs Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Growth Rate 2018-2029 (K Units)
- Figure 7. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Short-acting Recombinant Human Erythropoietin Drugs Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of Epoetin-alfa
- Figure 10. Product Picture of Epoetin-beta
- Figure 11. Product Picture of Darbepoetin-alfa
- Figure 12. Product Picture of Others
- Figure 13. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type in 2022
- Figure 14. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Type (2018-2023)
- Figure 15. Short-acting Recombinant Human Erythropoietin Drugs Consumed in Anemia
- Figure 16. Global Short-acting Recombinant Human Erythropoietin Drugs Market: Anemia (2018-2023) & (K Units)
- Figure 17. Short-acting Recombinant Human Erythropoietin Drugs Consumed in Kidney Disorders
- Figure 18. Global Short-acting Recombinant Human Erythropoietin Drugs Market: Kidney Disorders (2018-2023) & (K Units)
- Figure 19. Short-acting Recombinant Human Erythropoietin Drugs Consumed in Others
- Figure 20. Global Short-acting Recombinant Human Erythropoietin Drugs Market: Others (2018-2023) & (K Units)
- Figure 21. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2022)
- Figure 22. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Application in 2022

Figure 23. Short-acting Recombinant Human Erythropoietin Drugs Sales Market by Company in 2022 (K Units)

Figure 24. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Company in 2022

Figure 25. Short-acting Recombinant Human Erythropoietin Drugs Revenue Market by Company in 2022 (\$ Million)

Figure 26. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Company in 2022

Figure 27. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Geographic Region (2018-2023)

Figure 28. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Geographic Region in 2022

Figure 29. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales 2018-2023 (K Units)

Figure 30. Americas Short-acting Recombinant Human Erythropoietin Drugs Revenue 2018-2023 (\$ Millions)

Figure 31. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales 2018-2023 (K Units)

Figure 32. APAC Short-acting Recombinant Human Erythropoietin Drugs Revenue 2018-2023 (\$ Millions)

Figure 33. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales 2018-2023 (K Units)

Figure 34. Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue 2018-2023 (\$ Millions)

Figure 35. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales 2018-2023 (K Units)

Figure 36. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue 2018-2023 (\$ Millions)

Figure 37. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country in 2022

Figure 38. Americas Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country in 2022

Figure 39. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2018-2023)

Figure 40. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2018-2023)

Figure 41. United States Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 42. Canada Short-acting Recombinant Human Erythropoietin Drugs Revenue

Growth 2018-2023 (\$ Millions)

Figure 43. Mexico Short-acting Recombinant Human Erythropoietin Drugs Revenue

Growth 2018-2023 (\$ Millions)

Figure 44. Brazil Short-acting Recombinant Human Erythropoietin Drugs Revenue

Growth 2018-2023 (\$ Millions)

Figure 45. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Region in 2022

Figure 46. APAC Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Regions in 2022

Figure 47. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2018-2023)

Figure 48. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2018-2023)

Figure 49. China Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 50. Japan Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 51. South Korea Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 52. Southeast Asia Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 53. India Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 54. Australia Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 55. China Taiwan Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 56. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country in 2022

Figure 57. Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country in 2022

Figure 58. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2018-2023)

Figure 59. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2018-2023)

Figure 60. Germany Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 61. France Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 62. UK Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 63. Italy Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 64. Russia Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 65. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country in 2022

Figure 66. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country in 2022

Figure 67. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2018-2023)

Figure 68. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2018-2023)

Figure 69. Egypt Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 70. South Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 71. Israel Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 72. Turkey Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 73. GCC Country Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 (\$ Millions)

Figure 74. Manufacturing Cost Structure Analysis of Short-acting Recombinant Human Erythropoietin Drugs in 2022

Figure 75. Manufacturing Process Analysis of Short-acting Recombinant Human Erythropoietin Drugs

Figure 76. Industry Chain Structure of Short-acting Recombinant Human Erythropoietin Drugs

Figure 77. Channels of Distribution

Figure 78. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Forecast by Region (2024-2029)

Figure 79. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share Forecast by Region (2024-2029)

Figure 80. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share Forecast by Type (2024-2029)

Figure 81. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share Forecast by Type (2024-2029)

Figure 82. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share Forecast by Application (2024-2029)

Figure 83. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Short-acting Recombinant Human Erythropoietin Drugs Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/G0BDBFE79D8AEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G0BDBFE79D8AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970